Due to great interest in the development of BET protein bromodomain specific inhibitors that cross the blood-brain barrier (BBB) (14,15), an improved understanding of the RelA/BET complex and its function in GBM is important to design effective therapeutics. This evidence concerns the gene DNER and glioblastoma.